Project Grant W81XWH2210160

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $244,440 to the Albert Einstein College of Medicine to explore the role of cytolytic memory CD4+ T cells in protection against the liver stage of malaria caused by the Plasmodium falciparum parasite. The research aims to gain insights into the cellular immune determinants associated with natural clinical...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $184,109 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, with a project period from December 2024 to November 2026. The grant supports research to investigate the role of immune inhibitory receptors in modulating monocyte and T cell functions during subclinical Plasmodium falciparum malaria...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $832,071 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Seattle Children's Hospital to develop a universal transmission blocking vaccine (TBV) against multiple Plasmodium species that cause malaria. The project aims to characterize broadly neutralizing monoclonal antibodies (mAbs) and human naturally acquired immunity against mosquito stage antigens HAP2 and HAP2P, which can block...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to investigate the role of innate immune activation in thymic selection and T cell tolerance. The $2,457,262 award, effective July 1, 2024 through May 31, 2029, will enable the Regents of the University of Minnesota to: Test if thymic interferon (IFN) signaling provides T cell tolerance to IFN-stimulated...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $210,867 to Drexel University to conduct research on developing tolerogenic dendritic cells (TolDCs) as a cell-based therapy to induce immune tolerance in kidney transplant recipients. The key innovation is the use of "push/pull particle" TolDCs that contain microparticles loaded with a synergistic...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $501,011 to the University of North Carolina at Chapel Hill to conduct research on biodegradable polymeric microparticles comprised of acetalated dextran (Ace-Dex) and their ability to induce immune tolerance. The key objectives of this 5-year grant are to: 1) characterize the protein corona on the surface of...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,074,434.37 Project Grant to the Massachusetts General Hospital under the Allergy and Infectious Diseases Research program (CFDA 93.855) on March 17, 2021 with a completion date of July 12, 2021. The grant funding supports research to develop protocols to induce tolerance in non-human primate heart allograft recipients without chronic immunosuppression. The awardee will test approaches to either...

This federal Project Grant award of $791,864, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify the molecular factors that control chromatin organization and gene regulation in the human malaria parasite Plasmodium falciparum. The key objectives of the project are to elucidate the importance of long non-coding RNAs (lncRNAs) in parasite development, virulence, and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $708,202 to Brown University to identify novel vaccine candidates for Plasmodium falciparum malaria. The key objectives are to discover targets of naturally acquired immunity to severe malaria and develop them as blood-stage vaccine candidates. The project involves a case-control study in Kenya to identify infants and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $231,131 to Duquesne University to develop and evaluate an injectable 3D-clustered human fibroblastic reticular cell (FRC) formulation for expanding regulatory T cells (Tregs). The goal is to leverage FRC-mediated tolerance to prevent allograft rejection in transplant recipients, an alternative to the current...